

## MAHARAJA RANJIT SINGH PUNJAB TECHNICAL UNIVERSITY BATHINDA-151001 (PUNJAB), INDIA

(A State University Estb. by Govt. of Punjab vide Punjab Act No. 5 of 2015 and Approved u/s 2(f) & 12 (B) of UGC; Member AIU)

## Department: Pharmaceutical Sciences & Technology

Program: <u>M. Pharmacy (Pharmaceutics)</u>

## **Duration (Hrs)** Statement PS01 PSO2 PSO3 PSO4 PSO5 PSO6 PSO8 PO5 P06 PSO7 P01 P02 PO3 P04 õ Semester Subject S Code Credit LΤΡ Chemicals and Excipients 1 1 1 2 2 3 2 2 <u>C</u>01 Modern Pharmaceutical Analytical Techniques The analysis of various drugs 1 1 1 2 2 2 2 2 MPH101T C02 0 in single and combination 60 4 40 dosage forms Theoretical and practical 1 1 1 2 2 3 1 2 1 3 CO3 skills of the instruments 2.33 2.6 Avg. 666 333 1 1 1 1 1 2 2 67 1 2 1 3 The various approaches for 2 2 2 2 1 1 2 1 MPH102T delivery system Drug 400 development of novel drug C01 60 -4 delivery systems.

## **COURSE ARTICULATION MATRIX (STUDY SCHEME: 2017)**

						C02	The criteria for selection of drugs and polymers for the development of delivering system	1	2	1		1	2	2	1		1		2
						CO3	The formulation and evaluation of Novel drug delivery systems		2	1		1	3	2	2		2	1	2
	Avg.							1	2	1		1	2.3 333 33	2	1.6 666 67		1.33 333 3	1	2
						C01	The elements of preformulation studies			1		1	2	2	2		2		2
aceutics	Т					C02	The Active Pharmaceutical Ingredients and Generic drug Product Development	1		1		1	2	1		2		1	2
n Pharma	MPH103	1	4	60	400	CO3	Industrial Management and GMP Considerations.	1	1				2	2	2	1	2		2
Mode						CO4	Optimization Techniques & Pilot Plant Scale Up Techniques	2	1				2	2	2		2		2
						CO5	Stability Testing, sterilization process & packaging of dosage forms.	1		1		1	1	2	2		2		2
		Av	/g.																
								1.2 5	1	1		1	1.8	1.8	2	1.5	2	1	2
ry Affairs	104T		4	Q	0 0	C01	The Concepts of innovator and generic drugs, drug development Process	1	1				2	2	2		2	1	2
Regulato	MPH		7	9	4 (	C02	The Regulatory guidance's and guidelines for filing and approval Process	1	1					1	2		2	2	2

						CO3	Preparation of Dossiers and their submission to regulatory agencies in different countries	1	1						2	2	2			2
						CO4	Post approval regulatory requirements for actives and drug products	1	1						2	2	2			2
						CO5	Submission of global documents in CTD/ eCTD formats	1	1						2	2	2			2
						009	Clinical trials requirements for approvals for conducting clinical trials	1	1						2	2	2			2
						C07	Pharmacovigilence and process of monitoring in clinical trials.	1	1								1			
Avg.								1	1					2	1.8 333 33	2	1.85 714 3		1.5	2
						C01	The elements of performulation studies	1		1			1	2		2	2	2		2
tical I						C02	Optimization Techniques & Pilot plant scale up techniques		1		1		1	2		2	1	2		1
eutics Prac	PH105P	1	9	180	006	CO3	The various approaches for development of novel drug delivery systems	1	1				1	1	1	2	1	2	1	
Pharmace	Σ					C04	The criteria for selection of drugs and polymers for the development of delivering system	1				1	1	1		2	2	1		
						CO5	The analysis of various drugs in single and combination dosage forms	2	1				1	1		2	2	2		2
Avg.								1.2 5	1		1	1	1	1.4	1	2	1.6	1.8	1	1.66 666 7

Molecular Pharmaceutics						C01	The various approaches for development of novel drug delivery Systems		1	1		2	1	2		1	1			
	MPH201T	2	4	60	400	C02	The understanding of critical variables (material and process) for the development of novel drug/ gene delivery systems.		1	1		1		1			1			
						CO3	The formulation, evaluation & application of novel drug/ gene delivery systems.		1	1		1			1		1			
Avg.									1	1		1.3 333 33	1	1.5	1	1	1			
Advanced Biopharmaceutics and Pharmacokinetics						C01	The basic concepts in biopharmaceutics and pharmacokinetics	1	1		1	1		1			2	2		
					400	C02	The use raw data and derive the pharmacokinetic models and parameters the best describe the process of drug absorption, distribution, metabolism and elimination	1	1		1	1					2	2		
	MPH202T	2	4	60		400	400	CO3	The critical evaluation of biopharmaceutic studies involving drug product equivalency	1	1		1	2		2				1
						C04	The design and evaluation of dosage regimens of the drugs using pharmacokinetic and biopharmaceutic parameters	1	1		1	1		2		1		2		
						CO5	The potential clinical pharmacokinetic problems and application of basics of pharmacokinetic	1	1		1	1		2				2		
Avg.								1	1		1	1.2		1.7 5		1	2	1.8		

						CO1	History of Computers in Pharmaceutical Research and Development		1							1	2	
						C02	Computational Modeling of Drug Disposition		1			1			2		2	1
elopment						CO3	Computers in Preclinical Development		1			1	1		2	1	2	
Drug Deve	1203T	2	4	0	0 0	C04	Optimization Techniques in Pharmaceutical Formulation		1			2		2			2	1
Computer Aided I	MPH			θ	4	CO5	Computers in Market Analysis		1					2				
						C06	Computers in Clinical Development		1			1	2	2			2	1
						C07	Artificial Intelligence (AI) and Robotics		1				1	2	1	3		
						C08	Computational fluid dynamics(CFD)		1			1		2			1	
		Av	/g.						1			1.2	1.3 333 33	2	1.66 666 7	1.66 666 7	1.83 333 3	1
icals						C01	Key ingredients used in cosmetics and cosmeceuticals	1	1		1	2		1	1		2	2
osmeceut	04Т					C02	Key building blocks for various formulations	1	1		1	1		2	2			2
Cosmetics and Cos	MPH20	2	4	60	4 0 (	CO3	Current technologies in the market	1	1		1		2					1
						C04	Various key ingredients and basic science to develop cosmetics and cosmeceuticals	1	1		1	1	1	2	2		2	2

						CO5	Scientific knowledge to develop cosmetics and cosmeceuticals with desired Safety, stability, and efficacy.							2		2	2		2	1
Avg.																1.7				
	1							1	1				1	1.5	1.5	5	1.75		2	1.6
maceutics Practical II						C01	Various key ingredients and basic science to develop Novel drug delivery system.	1		1			1	2		2		1	2	1
			6			C02	Optimization Techniques in pharmaceutical formulation using factorial design		1		1		1	1		2	1		2	1
	MPH205P	2		180	006	CO3	The use raw data and derive the pharmacokinetic models and parameters the best describe the process of during absorption, distribution, metabolism	1	1				1	1		2	1	1	2	
Ph						CO4	The formulation and evaluation of novel drug delivery systems	1				1	1	1	1	2	1	1	2	1
						CO5	Drafting of various pharmaceutical Process related documentation	2	1				1			2	2	1	2	
Avg.								1.2 5	1	1	1	1	1	1.2 5	1	2	1.25	1	2	1

Enter Correction levels 1, 2 or 3 as defined below:

1. Slight (Low) - upto 30%

2. Moderate (Medium) – above 30% and upto70%

3. Substantial (High) – above 70%

-----

So on...... (1<sup>st</sup> semester to last semester)